Interleukin-8 (IL-8
OCAL ACCUMULATION of neutrophils in inflamma-
L tory disease states is predominantly regulated by release of chemotactic substances and a recently recognized group of cytokines, the interleukin-8 (IL-B)/monocyte chemotactic and activating factor (MCAF) family of chemokines.I4 Chemotactic activity induced by IL-8 is associated with the induction of numerous additional functions in neutrophils. IL-8 increases adhesion of neutrophils to unstimulated endothelial cells in vitro, whereas binding of neutrophils to endothelial cells preactivated by IL-1, tumor necrosis factor (TNF), or lipopolysaccharide (LPS) is inhibited.5,6 IL-8 induces expression of adhesion molecules and complement receptor type-I' and induces the release of several neutrophilic proteins.* Secretion of IL-8 has been detected in many cell types, including monocytes/macrophages, T lymphocytes, fibroblasts, endothelial cells, granulocytes, and
In most of these cells, only small amounts of IL-8 are produced constitutively. However, bacterial products, viruses, mitogens, phorbol esters, and the proinflammatory cytokines IL-1 and TNF-a are potent inducers of IL-8."3'2,L4 Thus, in inflammatory responses, IL-8 production can be induced either directly by microbial components or indirectly by cytokines that are secreted in response to microbial stimuli.
Counterbalance of exogeneously induced cytokine secretion represents a crucial prerequisite for the regulation of many biologic responses to prevent harmful local or systemic damage. Thus, downregulation of IL-8 production results in termination of neutrophil attraction and limits local inflammatory responses. IL-8 gene expression and the release of biologically active IL-8 have been inhibited with glucocorticoids,'5 IL-4,16 and IL-10,'' but little is known about the mechanisms of these effects.
Interferons (IFNs) induce a broad spectrum of activities in many cell types comprising activating and inhibitory signals." They have been found to activate macrophages and enhance the production of inflammatory ~y t o k i n e s . '~,~~ However, IFNs-a/P have also been reported to inhibit inflammation after local LPS The antiinflammatory activities of IFN may depend on increased expression of IL-1 -receptor antagonist22 and downregulation of IL-8 as saccharide-stimulated polymorphonuclear phagocytes IFN failed to suppress IL-8 expression. In untreated patients with CML, a constitutive expression of IL-8 mRNA was detected in freshly isolated PBMNC that was markedly reduced 5 hours after therapeutic application of IFN-a. The mechanism of IL-8 downregulation was studied more in detail in the THP-1 cell line. The experiments showed that de novo protein synthesis was not required for the inhibitory effect. RNA decay analysis and nuclear run-on assays suggest that in THP-1 cell line the inhibition of IL-8 expression is predominantly regulated at the posttranscriptional level. 
MATERIALS AND METHODS
Recombinant human-IFN-a2b (rh-IFN-a2b) with a specific activity of 1.8 x lo8 U/mg was purchased from Essex Pharma (Miinchen, Germany). rh-IFN-8 (3.0 X 10' U/mg) was kindly provided by Asta Pharma (Frankfurt, Germany), rh-granulocyte-macrophage colony-stimulating factor (rh-GM-CSF) by Sandoz AG (Niimberg, Germany), rh-IL-4 by Shering Plough (Kenilworth, NJ), and rh-TNF-a (6.6 X lo6 U/mg) by Knoll AG (Ludwigshafen, Germany). LPS was purchased from Sigma Chemicals (Deisenhofen, Germany), actinomycin-D and cycloheximide from Merck Inc (Darmstadt, Germany), and ~u~~P-labeled nucleotides from Amersham Buchler (Braunschweig, Germany).
Isolation of blood cells. Peripheral blood mononuclear cells Three experiments were performed in triplicates, and data from one representative experiment are presented a s mean f SEM. Concentrations used were LPS at 10 pg/mL and IFN-u a t 1,000 U/mL.
Materials.
(PBMNC) were isolated from the peripheral blood (PB) of healthy donors and CML patients in chronic phase after informed consent by centrifugation over Ficoll-Hypaque density gradient (Biochrom, Berlin, Germany). Polymorphonuclear phagocytes (PMN) were isolated from the PB of healthy donors by centrifugation over 3% dextrane as described else~here.'~ The purity of PMN was shown to be greater than 98% by differential morphologic analysis of cytospin preparations. BM samples were obtained after informed consent from normal BM transplant harvests. PBMNC, PMN, or myelomonocytic THP-I cells were incubated in RPMl 1640 medium (Biochrom, Berlin, Germany) containing 10% fetal calf serum (FCS) (Biochrom), penicilCell ciihire. BM stromal cell cultures were essentially obtained as described previously2' with some modifications. Briefly BM mononuclear cells separated by centrifugation over Ficoll-Hypaque were incubated at a cell density of I X IO6/mL in 25 cm2 tissue flasks at 33°C in culture medium consisting of RPMl 1640 supplemented with 10% FCS, 10% horse serum, I .O pmol/L hydrocortison (Sigma), and the additives as indicated above. In weekly intervals, cultures were fed by replacing 75% of culture medium. When cultures were covered more than 80% by adherent cell. primary cultures were treated with trypsin-EDTA (Biochrom); detached stromal cells were pooled and expanded in new culture flasks at a ratio of 1 5 . The adherent cells were incubated under the same culture conditions until cultures became confluent again. By this culture method, homogenous stromal cell layers were obtained that were morphologically and functionally comparable in different culture flasks. Hydrocortison was removed from these cultures a few days before use for RNA and protein analysis. 1L-8 protein was measured in the culture supernatants of stromal cells after incubation for 24 hours with various factors as indicated in the Results section. For RNA analysis, the factors as indicated were added to parallel culture flasks from the same donor. After 6 hours. cells were lysed directly in the culture flask with guanidinium-isothiocyanate and processed as described below.
Northern blot ana/wis. Total cytoplasmic RNA was purified from PBMC, PMN, or THP-I cells using the single step method of guanidinium/phenol-chloroform extraction as described previo u s l~?~ A total of I5 pg RNA was subjected to electrophoresis on a I ?h agarose-formaldehyde gel and transferred onto nylon membrane (Hybond-N: Amersham Buchler). Blots were hybridized to ~'~P-labeled cDNA probes using random primer DNA labeling kit (Boehringer, Mannheim, Germany) and after washing were ex-
Stromal cell ciilrrire.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From IL-8 ELISA. Cells were cultured in medium for 24 hours with or without factors as indicated in Results section, and IL-8 concentration was measured using Quantikine Human IL-8 Immunoassay (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
RESULTS
Effect of IFN-a on e,vpre.wion and secretion of IL-8 in normal h-PBMNC. Expression of IL-8 mRNA was studied in PBMNC from healthy donors immediately after isolation and after incubation with IFN-a in vitro. Examination of RNA samples separated directly from PBMNC of 5 normal donors showed no constitutive expression of IL-8 (as shown in one representative experiment in Fig IA) . After short-term incubation of these cells in culture medium alone, a significant enhancement of IL-8 mRNA was observed, as has been described recently by ~t h e r s . '~ However, when IFN-a (3,000 U/mL) was added to the cultures, the induction of IL-8 transcripts was markedly inhibited (Fig IA) .
In PBMNC obtained from 8 healthy donors (Fig 1 B) , the release of IL-8 protein was significantly inhibited by IFN-a. IFN-a (1,OOO U/mL) decreased the level of IL-8 from 17.01 f 3.18 ng/mL in control cultures to 4.59 f 1.69 ng/mL (mean 5 SEM, P c .01). thus representing a reduction of 73% 5 5.46% (95% confidence interval, 60.1% to 85.9%). Exogenously induced IL-8 secretion was also inhibited by IFN-a, as shown in Fig IC, in cultures of PBMNC that were stimulated with LPS. The effect of IFN-a was concentrationdependent between 30 and 1,000 U/mL, and substantial inhibition of more than 60% was already observed at 100 U/mL (Fig 2) . patients in chronic phase inhibited the spontaneous expression of IL-8 mRNA as observed in control cultures (Fig 3A) . Rehybridization of the filters with a cDNA probe for the IFN-inducible protein MxA showed that IFN-a was active in the cultures as shown by strong induction of MxA-gene expression. Therapeutic administration of IFN-a to CML patients caused a comparable decrease of mRNA expression as seen in vitro. RNA was prepared from PBMNC of CML patients before and 4 to 6 hours after subcutaneous injection of a single dose of IFN-cu2b (5 X IO6 IU). In contrast to normal controls, freshly isolated PBMNC from 7 of 12 CML patients showed significant expression of IL-8 mRNA. As shown in Fig 3B. for three typical experiments. the constitutive expression of IL-8 mRNA was almost completely abolished by the IFN treatment. PBMNC of IFN-treated patients retained the capacity to produce IL-8 in vitro. This de novo induction of IL-8 could again be downregulated by IFN (Fig 4) . suggesting that IFN exerts a direct regulatory effect on IL-8 production rather than causing a depletion of IL-8-producing cells from circulation. These ex vivo results show that the inhibitory effect on IL-8 expression can be achieved by systemic administration of moderate, therapeutic doses of IFN-a. BM stromal cells were incubated with culture medium, LPS (25 pg/mL) or TNF-a (500 U/mL) with or without IFN-a (3,000 U/mL), respectively. After 6 hours. RNA was prepared and Northern blot analysis was performed. As shown in Fig 5A, stromal cells expressed low levels of IL-8 mRNA constitutively, which could be further enhanced by TNF and LPS. IFN-a significantly inhibited the constitutive expression of IL-8 and reduced IL-8 expression induced by LPS or TNF. Inhibition of mRNA expression wasaccompanied by a decreased release of IL-8 into the culture supematants (Fig 5B) .
cffcxv on lL-8 erprmsion in PMN. IL-8 production was also observed in PMN upon stimulation with LPS. Accumulation of IL-8 mRNA was readily detectable but was not inhibited by IFN-a under conditions that nearly blocked expression in PBMNC and BM stromal cells (Fig 6) . IL-8 production by PMN stimulated with granulocyte-CSF or LPS was also unaffected by IFN-a (data not shown). In these experiments. PMN could be shown to respond to IFNa. as indicated by expression of the IFN-responsive gene. MxA (Fig 6) . For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Significant inhibition was also obtained with IL-4, and IL-8 mRNA was completely blocked when IFN-a and IL-4 were combined (Fig 7) . Hybridization of the blots to the MxA probe again confirmed the specific activity oftype-I lFNs in this cell population.
The possibility ofa posttranscriptional downregulation of IL-8 expression was evaluated using actinomycin-D. As shown in Fig 8, in IFN -treated cells IL-8 mRNA decayed more rapidly than in the controls suggesting the involvement of a posttranscriptional mechanism.
Nuclear run-on assays were performed in THP-l cells treated with IFN-a and TNF alone or in combination (Fig  9) . TNF enhanced the transcription of IL-8 mRNA, and this effect was not modified by IFN-a, indicating that the inhibition of IL-8 expression by IFN occurs at a posttranscriptional level. The nuclear RNA probes obtained were also hybridized to the @-actin cDNA and to the plasmid PUC-19, and no effect of either cytokine was observed. Transcription of the MxA gene was clearly induced in presence of IFN-a, confirming the IFN-specific activity in this assay.
Act-D
The potential role of proteins induced de novo by IFN in the downregulation of IL-8 expression was studied in THP-I cells and PBMNC using cycloheximide (CHX) as a protein synthesis inhibitor (Fig IO) . CHX In PBMNC from normal donors and CML patients and in other cellular sources, IL-8 mRNA expression and protein secretion induced by in vitro cultivation were clearly reduced by IFN-a in a dosedependent manner. In THP-I cells the action of IFN was compared with IL-4 which has been previously shown to inhibit IL-8 expression in human monocytes.'6 These experiments showed a comparable inhibitory effect of both cytokines. Furthermore, IFN-a and IL-4 seemed to synergize in downregulation of the IL-8 expression. The effect of IFN was independent of the type of stimulation used for IL-8 induction. Marked downregulation of IL-8 expression was observed in spontaneous cytokine production in vitro in PBMNC and was also observed after stimulation of the different cell types tested with LPS or cytokines such as TNF-a or GM-CSF.
In contrast to normal donors, a constitutive expression of IL-8 mRNA was observed in PBMNC of patients with CML. Overexpression of cytokines by CML cells has been observed by several groups, and autocrine or paracrine secretion ofgrowth factors has been suggested to contribute to the uncontrolled expansion of the leukemic cell populat i~n .~' .~' However, whether constitutive expression of IL-8 plays a pathophysiologic role in CML development remains to be determined. Downregulation of IL-8 expression has also been observed in RNA samples obtained from patients after the first dose of IFN-a in a clinical trial, thus confirming an in vivo relevance of this mechanism.
In purified PMN, IFN-a failed to suppress IL-8 expression at both the RNA and protein levels. This was not due to a lack of sensitivity by PMN to IFN-a, induced. Therefore, the mechanisms of IL-8 production appear to be differentially regulated depending on the source and on the state of differentiation of the expressing cells.
Regulation The mechanism of IFN action in suppressing IL-8 production remains unclear. In presence of the RNA synthesis inhibitor actinomycin-D, an accelerated degradation of IG8 mRNA in THP-1 cells was observed, suggesting a posttranscriptional mechanism. The data from nuclear run-on experiments are in keeping with this point of interaction with IL-8 synthesis. In contrast, Oliveira et a123 showed that the inhibition of IL-8 production is most pronounced at the transcriptional level. This discrepancy could be explained by the different cellular systems that were used by both groups. However, it has been discussed by these investigators that IFN might, in addition, block IL-8 synthesis at another level. A differential regulation of IL-8-mRNA expression in different experimental systems is not unprecedented and has been described for induction of IL-8 by proinflammatory cytokines at both the transcriptional3' and posttranscriptional level.3s Thus, control of IL-8 expression by enhancing and suppressing cytokines may be regulated by more than one mechanism and might take place at a transcriptional as well as a posttranscriptional level. Interestingly, de novo protein synthesis is not required for IFN-induced downregulation in hematopoietic cells, confirming the results described in human fibroblast^.'^ The present data show a profound inhibitory effect of type-I IFNs on IL-8 production in hematopoietic cells in vivo and in vitro and in BM stromal cell cultures. IFNs appear to differentially regulate the expression of various cytokines associated with inflammatory responses. The downregulation of IL-8, a prototypic inflammatory chemokine, by IFN, which by itself is induced by microbial stimuli, suggests a physiologically regulatory role of IFNs in limiting accumulation and activation of neutrophils; therefore, IL-8 downregulation by IFN may inhibit inflammatory processes.
